INTRODUCTION
Streptococcus pneumoniae is one of the most common agents of pneumonia, meningitis, acute otitis media, and sinusitis in children. 1, 2 It accounts for high morbidity and mortality rates in children under the age of fi ve years and adults over the age of 65 years, 2 especially in developing countries. 3 The World Health Organization estimates that from 800 thousands to one million children die every year due to invasive pneumococcal disease, and more than 90% of the deaths occur in developing countries. 4 Meningitis is one of the least common manifestations of pneumococcal disease and has the highest rates of morbidity (late neurological sequelae in approximately 40% 5 to 58% 6 ) and lethality (up to 50%6) in developing countries. In the USA, prior to the appearance of the Haemophilus infl uenzae type B (Hib) conjugate vaccine, approximately 95% of the meningitis cases in children under the age of two years were caused by the bacteria Hib, meningococcus, and pneumococcus. 7 In Brazil, pneumococcus is the second causative agent of bacterial meningitis, and in the 2001-2006 period, its mean lethality coeffi cient was 30%, much higher than those of meningococcus (17.6%) and Hib (19.8%). 8 The clinical course of the pneumococcal disease is infl uenced by several factors, such as treatment adequacy. The treatment for pneumococcal infections is based on initial antibiotic therapy, which is usually empirical regarding the etiology and in vitro susceptibility to antimicrobial agents. Based on bacterial isolation in culture and antimicrobial susceptibility tests, antibiotic therapy can be then properly adjusted. Penicillin is the drug of choice for many pneumococcal diseases; 1 however, with the increasing report of penicillinresistant strains since the 1980s, alternative regimens have been proposed.
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The prevention of invasive disease is mainly based on active immunization. 1, 2 According to the capsular polysaccharide antigen, 91 different serotypes, 11, 12 contained in 46 pneumococcal serogroups, 13 have been described so far. A 7-valent vaccine (PCV7. Prevenar®. Pfi zer/Wyeth Pharmaceuticals, Inc.) containing the capsular polysaccharide of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, conjugated with a protein carrier, was licensed in the USA in 2000. 14 The immunogenicity of the polysaccharide is widened by the covalent binding with the protein molecule, particularly in children under the age of two years, and the vaccine protects against nasopharyngeal colonization by the serotypes it contains.
14 The following two conjugate vaccines have been recently licensed in several countries: the 13-valent (PCV13. Prevenar13® Pfi zer/Wyeth Pharmaceuticals, Inc.) produced with the same protein carrier according to the same conjugation process, which, compared to PCV7, adds the capsular polysaccharide antigen of serotypes 1, 3, 5, 6A, 7F, and 19A; 15 and the 10-valent (PCV10. Synfl orix®. GlaxoSmithKline Biologics AS), which uses different protein carriers and, as compared to PCV7, adds serotypes 1, 5, and 7F. 15 Because the antibiotic resistance pattern and pneumococcal serotype prevalence vary in different populations, in different geographical regions and, probably, over time, establishing the profi le of the most prevalent serotypes in a certain community and knowing the resistance rates are important to better assess vaccine coverage and to support the choice of initial empiric treatment.
OBJECTIVES
To document the serotype profi le and susceptibility to antimicrobial agents of pneumococcal strains obtained from patients hospitalized with meningitis at the Hospital das Clíni-cas of the Universidade Federal de Uberlândia (HC-UFU), in addition to assessing the implications for the antipneumococcal vaccine coverage rates.
PATIENTS AND METHODS
This is a prospective, case-series, laboratory-surveillance study, whose laboratory data of serotyping and in vitro susceptibility to antimicrobial agents of invasive pneumococcal strains were obtained from patients admitted to the HC-UFU. The index case is a pneumococcal strain isolated at the Clinical Analysis Laboratory from clinical specimens (blood or cerebrospinal fl uid) of a patient hospitalized with meningitis. Aseptically obtained specimens were properly processed and inoculated in hemoculture bottles (blood sample) or in chocolate-agar and blood-agar plates (other sample types) right after collection and immediately after arrival at the laboratory. Only one pneumococcal isolate per patient per hospitalization was considered in the study. The pneumococcal strains were isolated and identifi ed at the HC-UFU according to internationally described methods and subsequently sent to the Bacteriology Sector of the Instituto Adolfo Lutz (IAL), in the city of São Paulo, for specimen confi rmation, serotyping, and determination of in vitro susceptibility to antimicrobial agents. 16 Pneumococcal strains were lyophilized in 20% skim milk and properly catalogued. The following two fi ndings characterized a case of meningitis: pneumococcal isolation in the cerebrospinal fl uid; or clinical and laboratory fi ndings of meningitis accompanied by the isolation of the agent in blood.
Antimicrobial susceptibility was assessed by using the disk diffusion test with oxacillin (1 µg), tetracycline, ofl oxacin, chloramphenicol, erythromycin, sulfamethoxazole-trimethoprim (cotrimoxazole), vancomycin, and clindamycin in MuellerHinton agar plates supplemented with 5% sheep blood according to the standardized technique. 17, 18 Oxacillin-resistant strains (cleared area ≤ 19 mm) underwent subsequent determination of the minimum inhibitory concentration (MIC) of penicillin by using the broth microdilution method and were considered according to the criteria of the Clinical and Laboratory Standards Institute (CLSI), 2008 19 as follows: susceptible [S], MIC ≤ 0.06 mg/mL; and resistant [R], MIC ≥ 0.12 mg/mL, for strains obtained from patients with meningitis. Oxacillin-resistant strains also underwent MIC determination for ceftriaxone and were considered as follows: susceptible, MIC ≤ 0.5 µg/mL; intermediately resistant (IR), MIC = 1 µg/mL; and fully resistant (FR), MIC ≥ 2 µg/mL for strains obtained from patients with meningitis. 20 Oxacillin-susceptible strains (cleared area > 19 mm) were considered susceptible to penicillin and did not undergo MIC determination, according to the recommendation of the CLSI, 2007. 21 The cut-off points defi ned for penicillin 19 and ceftriaxone 20 were applied to the results (MIC) obtained during the study period, and maintained in a database.
Serotyping was performed by use of the Neufeld Quellung reaction, a technique previously described 22 by using polyclonal antisera. 11 Data from April 1999 to April 2009 were obtained and the results were submitted to statistical analysis. The results were analyzed in two time periods, considering the reports on the increase in resistance rates over time. 23, 24 Only two periods of time were chosen because of the limited size of the sample.
For comparing the proportions of the pattern of antimicrobial susceptibility in the different time periods and age ranges, the chi-square test (χ 2 ) was used. Tests of normality and homogeneity of the samples were used whenever necessary. The level for rejecting the null hypothesis was fi xed as 5% (P < 0.05).
The study was approved by the Committee on Ethics in Research of the Universidade Federal de Uberlândia (CEP/UFU, protocol 210/08).
RESULTS
From April 1999 to April 2009, 72 pneumococcal strains obtained from patients with meningitis were sent to the IAL and assessed. Forty-six (63.9%) strains originated from males, and age ranged from one month to 82.2 years (mean, 18.4 ± 22.9 years; median, 5.2 years; 25th percentile, 5.2 months; and 75th percentile, 36 years). The number of isolations per age bracket was 33 in children up to 24 months, two in children from 25 to 60 months, nine in children from 61 months to 12 years, 23 in patients from over 12 to 60 years, and fi ve in patients older than 60 years. The number of samples studied per year obtained from 1999 to 2009 was 6, 11, 8, 7, 7, 8, 5, 9, 6, 3 , and 2, respectively. The sources of collection were cerebrospinal fl uid in 66 samples (91.7%) and blood in six samples (8.3%). Overall lethality rate of 25% (18/72) was lower than that of children aged two years or less (36.4%) and that of adults over the age of 60 years (80%).
Twenty-four different serotypes were identifi ed and the most common are shown in (Table 3 ; P = 0.000). The maximum penicillin and ceftriaxone MIC were 4 µg/mL and 2 µg/mL, respectively. No resistance to chloramphenicol, ofl oxacin, rifampicin or vancomycin was observed.
DISCUSSION
Despite the small size of the population studied, similarities with the results of other national [25] [26] [27] [28] [29] [30] [31] [32] and Latin-American [25] [26] [27] [28] surveys could be identifi ed. The profi le of the most frequently found serotypes in developing countries has been confi rmed, 14, 19F, 3, 7F, 6A/6B, 10A, 18C, 23F, 5, and 1, with an emphasis on the high prevalence of serotypes 1 and 5, commonly found in Latin America. 13 28 The analysis of the most frequently found serotypes in children with meningitis up to the age of fi ve years indicated a 76.9% coverage rate of the PCV7 vaccine, including serotype 6A. According to data in Table 1 , the vaccine coverage in the population under the age of fi ve years studied should be 71.3% (79.8% when including serotype 6A) and would not include serotypes 1, 3, and 5, also isolated. Nevertheless, serotypes 6B, 14, 19F, and 23F, among which penicillin-resistant strains can be found, would be covered (100% vaccine coverage). The PCV10 vaccine coverage in the population here studied would be 82.8% (91.3% with serotype 6A), and the PCV13 vaccine coverage would increase to 94.2%.
The comparison of the proportions according to age bracket (Table 1) suggests a predominance of serotypes 14, 6A, 6B, and 18C in children aged up to fi ve years and of serotype 3 in patients over that age, a fact also reported in other studies. 31, 32 Serotype 3, associated with severe forms of pneumonia in adults, 13, 29 is also an important cause of invasive disease in newborns and infants, justifying its inclusion in a vaccine to protect children under the age of two years. 13 In our survey, serotype 3 is one of the most commonly found in patients with meningitis, and also found in children under the age of two years. The high frequency of serotypes 14, 6A, and 6B in invasive disease, especially in infants with meningitis, has already been reported in national [26] [27] [28] [29] [30] [31] [32] and Latin-American 26-28 studies. Although some serotypes have been associated with a particular disease, there is no exclusivity and different serotypes can cause different diseases. 13 Because they are non-completely dependent variables, the correlation of the serotype profi le with the disease type can be infl uenced by other factors, such as temporality and age. 13 However, serotype 18C has been more commonly associated with meningitis 13 and serotype 19A with pneumonia. 29 In this study, serotype 18C was detected in children under the age of fi ve years (8.5%) and serotype 19A, in only one patient over that age. Despite its low frequency in Brazil [25] [26] [27] [28] [29] and other LatinAmerican countries, serotype 19A is associated with penicillin resistance 13, 23, [30] [31] [32] and is currently an important emerging serotype in the USA, after the release of the heptavalent conjugate vaccine for universal use. 7, 13 In this study, the penicillin-resistance rate was 23.6% (17/72 strains) when all age brackets were considered, and 39.4% for ages up to two years (Table 2) . Those fi gures are greater than the 15% found when considering the different ages and nosologies, and greater than the 29.6% found when considering children up to two years, in that same population in 2003. 33 Those fi gures are close to those found in patients hospitalized with meningitis at other places: 20.3% at different ages and 24.3% in children aged up to fi ve years at the Brazilian Federal District; 32 36.4% in patients aged from one month to 15 years in the city of São Paulo; 30 and, in the city of Salvador, overall rate of 15.2% and predominance in children under the age of fi ve years (35%) as compared with older children (9%). Penicillin resistance has been restricted to serotypes 14 (11 strains), 19F, 23F (two strains each), 6B, and 19A (one of each), classically associated with drug resistance. 13 Those are the socalled "pediatric serotypes", responsible for a large number of infectious episodes in children. The age-dependent intrinsic characteristics of immunogenicity and the extensive exposure to antimicrobial agents have contributed, respectively, to the predominance among younger children and the development of penicillin resistance. 13, 23 This study could confi rm the increase in the proportion of penicillin-resistant strains related to age (39.4% up to two years versus 10.3% above that age; Table 2 Table 2 ; P = 0.003). The tendency towards an increase in penicillin resistance in Brazil over time has already been demonstrated in a Brazilian study 23 and has been associated with the emergence and dissemination of two international pneumococcal clones denominated Spain 9V -3 and Tennessee. [14] [15] [16] [17] [18] Theses clones, which express the capsule of serotype 14 and are characterized by drug resistance, have predominated in the southern and southeastern regions of Brazil since 1998. Of the 17 isolated penicillinresistant clones detected in the present study, 11 (64.7%) are serotype 14, and, thus, one can speculate that, at least partially, the increase in the proportion of resistant strains results from dissemination of the referred clones in that community.
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The nine ceftriaxone-resistant pneumococcal strains (fi ve IR strains and four FR strains) found in this study account for a 12.5% resistance rate, close to that reported in Brazilian laboratory surveillance studies 26-28 when using the current cut-off points for ceftriaxone. 20 Based on the invasive strains obtained from patients with meningitis in 2006, 26 2007, 27 and 2008, 28 a 11.9% rate of ceftriaxone resistance was detected, 9.1% being IR and 2.8% FR. Considering only children aged up to fi ve years, admitted with invasive disease (23.2% with meningitis) from 1999 to 2009, a 5.6% ceftriaxone-resistance rate was found in the same population assessed in this study. 34 The documented resistance rates for both penicillin and ceftriaxone vary depending on factors, such as geographical location, sample size, time and duration of the assessment, patient's age, and nosology. Usually, resistance tends to predominate in children, 23, [31] [32] [33] especially in those with meningitis, 23, 34 with increasing frequency 23, 32, 34 and intensity 23 over time in the communities not undergoing universal vaccination.
The most appropriate methodology to estimate pneumococcal disease rates in a community consists in clinical population surveillance, based on the laboratory identification of the agent. 7 That requires up-to-date data of population census and consistent techniques of accurate pneumococcal isolation and identification. This study used laboratory surveillance of invasive hospital-based strains, which is a limitation to conclusions. Epidemiological data should be carefully extrapolated, particularly for those diseases diagnosed and treated outside the hospital setting.
Local or regional pattern of drug susceptibility should be monitored to support the choice of the best empiric therapeutic regimen for invasive pneumococcal diseases. For the specifi c directed treatment, the antibiotic choice is infl uenced by the laboratory categorization (susceptible or resistant, according to the MIC) and every effort should be made in the search for the causative agent and determination of its susceptibility to antimicrobial agents.
Finally, the greatest impact on morbidity and mortality of pneumococcal meningitis results from its prevention through the universal use of the conjugate vaccine in the target population, similarly to what happened with the Hib and pneumococcal infection in the USA. 7 The decision of the Brazilian Ministry of Health to include the pneumococcal conjugate vaccine in the National Immunization Calendar of all children aged up to two years from this year on is of paramount importance.
